These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18781986)

  • 1. Endocannabinoids in liver disease and hepatic encephalopathy.
    Magen I; Avraham Y; Berry E; Mechoulam R
    Curr Pharm Des; 2008; 14(23):2362-9. PubMed ID: 18781986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocannabinoids in liver disease.
    Tam J; Liu J; Mukhopadhyay B; Cinar R; Godlewski G; Kunos G
    Hepatology; 2011 Jan; 53(1):346-55. PubMed ID: 21254182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sirolimus on liver cirrhosis and hepatic encephalopathy of common bile duct-ligated rats.
    Wu KC; Huang HC; Chang T; Lee WS; Chuang CL; Hsin IF; Hsu SJ; Lee FY; Chang CC; Lee SD
    Eur J Pharmacol; 2018 Apr; 824():133-139. PubMed ID: 29444470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Endocannabinoids: therapeutic perspectives in chronic liver diseases].
    Lotersztajn S; Teixeira-Clerc F; Hezode C; Tran van Nhieu J; Deveaux V; Mallat A
    Gastroenterol Clin Biol; 2007 Mar; 31(3):255-8. PubMed ID: 17396081
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent advances in the understanding of the role of the endocannabinoid system in liver diseases.
    Huang L; Quinn MA; Frampton GA; Golden LE; DeMorrow S
    Dig Liver Dis; 2011 Mar; 43(3):188-93. PubMed ID: 20934397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cannabinoids in chronic liver diseases.
    Parfieniuk A; Flisiak R
    World J Gastroenterol; 2008 Oct; 14(40):6109-14. PubMed ID: 18985799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocannabinoids as novel mediators of liver diseases.
    Mallat A; Lotersztajn S
    J Endocrinol Invest; 2006; 29(3 Suppl):58-65. PubMed ID: 16751709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the endocannabinoid system in liver diseases.
    Caraceni P; Domenicali M; Giannone F; Bernardi M
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):65-77. PubMed ID: 19285261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis.
    Caraceni P; Viola A; Piscitelli F; Giannone F; Berzigotti A; Cescon M; Domenicali M; Petrosino S; Giampalma E; Riili A; Grazi G; Golfieri R; Zoli M; Bernardi M; Di Marzo V
    Liver Int; 2010 Jul; 30(6):816-25. PubMed ID: 19840245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.
    Mallat A; Lotersztajn S
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G9-G12. PubMed ID: 17975129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endocannabinoid system in chronic liver disease.
    Zamora-Valdés D; Ponciano-Rodríguez G; Chávez-Tapia NC; Méndez-Sánchez N
    Ann Hepatol; 2005; 4(4):248-54. PubMed ID: 16432489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The visual evoked potential in clinical hepatic encephalopathy in acute and chronic liver disease.
    Levy LJ; Bolton RP; Losowsky MS
    Hepatogastroenterology; 1990 Dec; 37 Suppl 2():66-73. PubMed ID: 2083938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of raloxifene on portal hypertension and hepatic encephalopathy in cirrhotic rats.
    Chang CC; Lee WS; Chuang CL; Hsin IF; Hsu SJ; Chang T; Huang HC; Lee FY; Lee SD
    Eur J Pharmacol; 2017 May; 802():36-43. PubMed ID: 28238769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocannabinoids and non-endocannabinoid fatty acid amides in cirrhosis.
    Ying-Ying Y; Lin HC
    Liver Int; 2010 Jul; 30(6):780-1. PubMed ID: 20408944
    [No Abstract]   [Full Text] [Related]  

  • 15. [Chronic hepatic encephalopathy in cirrhotic patients and spontaneous portacaval anastomosis. Portal angiographic and manometric study].
    Bauret P; Mirouze D; Bories P; Mourrut C; Bruel JM; Michel H
    Gastroenterol Clin Biol; 1989; 13(2):132-5. PubMed ID: 2707522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases.
    Pacher P; Gao B
    Am J Physiol Gastrointest Liver Physiol; 2008 Apr; 294(4):G850-4. PubMed ID: 18239059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hepatic encephalopathy.
    Córdoba J; Blei AT
    Am J Gastroenterol; 1997 Sep; 92(9):1429-39. PubMed ID: 9317058
    [No Abstract]   [Full Text] [Related]  

  • 18. Review article: the endocannabinoid system in liver disease, a potential therapeutic target.
    Basu PP; Aloysius MM; Shah NJ; Brown RS
    Aliment Pharmacol Ther; 2014 Apr; 39(8):790-801. PubMed ID: 24612021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased intracranial pressure and hepatic encephalopathy in chronic liver disease.
    Crippin JS; Gross JB; Lindor KD
    Am J Gastroenterol; 1992 Jul; 87(7):879-82. PubMed ID: 1615943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocannabinoids and liver disease--review.
    Gabbay E; Avraham Y; Ilan Y; Israeli E; Berry EM
    Liver Int; 2005 Oct; 25(5):921-6. PubMed ID: 16162147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.